A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461 on ClinicalTrials.gov · last registry update 2026-09-03
Recruiting now, toward 600 participants. Due to report 17 January 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41. Sponsors move these dates routinely; any movement since this site started watching is listed below. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 600
- Started
- 2026-08-24
- Primary completion
- 2028-01-17 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.